U.S. Oncology Drugs Market Research Report Information By Type (Chemotherapy, Targeted Therapy, Immunotherapy (Biologic Therapy), Hormonal Therapy, Other), By Application (Blood Cancer, Breast Cancer, Gastrointestinal Cancer, Prostate Cancer, Respiratory or Lung Cancer, Other)–Market Forecast Till 2032

U.S. Oncology Drugs Market Overview

U.S. Oncology Drugs Market Sizewas valued at USD 98.8 billion in 2022. The U.S. Oncology Drugs market industry is projected to grow from USD 114.1 Billion in 2023 to USD 361.4 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 15.50% during the forecast period (2023 - 2032).The rise in the prevalence of cancer disease and the rise in the incidence of various cancer conditions are the main market drivers anticipated to propel the U.S. Oncology Drugs market in the United States.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

U.S. Oncology Drugs Market Trends

• Immunotherapy Dominance is driving the market growth

One prominent trend in the U.S. Oncology Drugs market is the dominance of Immunotherapy. Immunotherapeutic agents, including immune checkpoint inhibitors and CAR-T cell therapies, have revolutionized cancer treatment by leveraging the body's immune system to target and eliminate cancer cells. The success of immunotherapy in various cancers, such as melanoma, lung cancer, and haematological malignancies, has led to its widespread adoption and ongoing research for expanding its applications. The trend highlights a paradigm shift towards precision medicine and targeted therapies that offer more effective and less toxic treatment options, representing a significant advancement in the landscape of oncology drugs.This factor drives the market CAGR.

Furthermore, another key trend shaping the U.S. Oncology Drugs market is the increasing focus on personalized medicine and targeted therapies. Advances in genomics and molecular diagnostics have allowed for a deeper understanding of the genetic basis of cancer, leading to the development of drugs that target specific molecular pathways involved in cancer growth. Targeted therapies offer the potential for more effective treatment with fewer side effects compared to traditional chemotherapy. The trend towards precision medicine is evident in the growing number of oncology drugs designed to target specific genetic mutations or proteins associated with particular cancer types. This approach improves treatment outcomes and underscores the ongoing evolution towards more tailored and patient-centric cancer care in the United States.Thus driving the U.S. Oncology Drugs market revenue.

U.S. Oncology Drugs Market Segment Insights

U.S. Oncology Drugs Type Insights

Based on Type, the U.S. Oncology Drugs market segmentation includes Chemotherapy, Targeted Therapy, Immunotherapy (Biologic Therapy), Hormonal Therapy, and Others. Targeted therapy emerges as the dominant category in the U.S. Oncology Drugs market due to its emphasis on precision medicine and the specific targeting of molecular pathways involved in cancer growth. These therapies are designed to interfere with specific molecules involved in cancer progression, addressing the unique characteristics of cancer cells. Additionally, immunotherapy, specifically biologic therapy, represents the fastest-growing category in the U.S. oncology drugs market, driven by its revolutionary approach and broad applicability across different cancer types. Biologic therapies harness the body's immune system to recognize and attack cancer cells, offering a novel and powerful treatment approach.

Figure1:U.S. Oncology Drugs Market, by Distribution Channel, 2022 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

U.S. Oncology Drugs Application Insights

The U.S. Oncology Drugs market segmentation, based on Application, includes Blood Cancer, Breast Cancer, Gastrointestinal Cancer, Prostate Cancer, Respiratory or Lung Cancer, and others. Breast cancer stands out as the dominant category in the U.S. Oncology Drugs market, driven by its high incidence rate and the comprehensive treatment landscape that includes a diverse array of therapeutic interventions. The prevalence of breast cancer across various demographics necessitates a robust pharmaceutical response, leading to the development of targeted therapies, hormonal treatments, and immunotherapies specifically tailored to address different subtypes of breast cancer. Additionally, immunotherapy is the fastest-growing category in the U.S. oncology drugs market, which is applied to respiratory or lung cancer. Advancements in immunotherapeutic approaches, particularly in non-small cell lung cancer, have led to a surge in research and the development of novel drugs. Immunotherapy has demonstrated unprecedented success in improving survival rates for lung cancer patients, with immune checkpoint inhibitors such as pembrolizumab and nivolumab gaining widespread adoption.

U.S. Oncology Drugs Country Insights

In the United States, the Oncology Drugs landscape reflects a dynamic and evolving approach to combating various cancer types. With breast cancer dominating due to its high incidence, the pharmaceutical focus is comprehensive, spanning targeted therapies, hormonal treatments, and immunotherapies tailored to different subtypes. The fastest-growing category centres on respiratory or lung cancer immunotherapy, showcasing remarkable advancements in addressing historically challenging conditions. The U.S. Oncology Drugs market underscores a commitment to precision medicine and innovative therapeutic approaches, focusing on improving patient outcomes and redefining the standard of care in the complex and diverse cancer treatment landscape.

U.S. Oncology DrugsKey Market Players& Competitive Insights

In order to extend their product lines, major market players are substantially investing in research and development, which would propel further growth in the U.S. oncology drugs market. In order to increase their market share, market players are also engaging in a range of strategic initiatives. Notable developments in this regard include the introduction of new products, contracts, mergers and acquisitions, increased investment, and cooperation with other businesses. The American oncology market needs to provide affordable products if it wants to grow and thrive in a more cutthroat and dynamic environment.

Major players in theU.S. Oncology Drugsmarket are attempting to increase market demand by investing in research and development operations, including GlaxoSmithKline PIc.,Novartis AG,Merck & Co. Inc.,Eli Lilly and Company,Amgen Inc.,Bayer, Celgene Corporation,Johnson & Johnson,Pfizer Inc.

Key Companies in the U.S. Oncology Drugs market include

• GlaxoSmithKline PIc.


• Novartis AG


• Merck & Co. Inc.


• Eli Lilly and Company


• Amgen Inc.


• Bayer


• Celgene Corporation


• Johnson & Johnson


• Pfizer Inc.

U.S. Oncology Drugs Industry Developments

May 2023:AbbVie Inc. announced the U.S. FDA approval for its EPKINLY, among the only drugs for treating patients with relapsed or refractory diffuse large b-cell lymphoma (DLBCL).

March 2023:Pfizer Inc. announced a merger agreement to acquire Seagen, Inc., a global biotechnology company manufacturing cancer medicines. The acquisition would strengthen Pfizer's capabilities and expertise inoncology.

U.S. Oncology Drugs Market Segmentation

U.S. Oncology Drugs Type Outlook

• Chemotherapy


• Targeted Therapy


• Immunotherapy (Biologic Therapy)


• Hormonal Therapy


• Other

U.S. Oncology Drugs Application Outlook

• Blood Cancer


• Breast Cancer


• Gastrointestinal Cancer


• Prostate Cancer


• Respiratory or Lung Cancer


• Other